SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live we ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Kura Oncology, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - Kura Oncology is expected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of -227.3% [3] - Revenues are projected to be $29.81 million, down 44.7% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 552.38% lower in the last 30 days, indicating a significant reassessment by analysts [4] - The Most Accurate Estimate for Kura Oncology is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.29% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with predictive power being significant for positive readings only [9][10] - Kura Oncology currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Kura Oncology was expected to post a loss of $0.57 per share but actually reported a loss of -$0.85, resulting in a surprise of -49.12% [13] - Over the past four quarters, Kura has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Apellis Pharmaceuticals is expected to report a loss of $0.39 per share, indicating a year-over-year change of -34.5% [18] - Apellis' revenue is projected to be $194.37 million, down 8.5% from the previous year, with an Earnings ESP of -3.07% [19][20]

Core Insights - Kura Oncology, Inc. is highlighted as one of the 20 best biotech stocks under $20 to buy now [1] - Leerink Partners has revised the price target for Kura Oncology to $20 from $25 while maintaining an Outperform rating, reflecting updates based on preliminary Q4 financial results [2] - Kura Oncology reported that its product KOMZIFTI generated $2.1 million in net sales during its first five weeks of commercial availability [3] - The company has outlined anticipated milestones for 2026, including expanding the use of ziftomenib and progressing current AML clinical investigations [4] - Kura Oncology is focused on developing targeted therapies for cancer and hematologic malignancies, with a pipeline of precision small-molecule inhibitors [5]

Core Insights - The article emphasizes the importance of identifying potential high-growth investment opportunities, specifically targeting small- and mid-cap companies through fundamental analysis of their business models, financials, and valuations [1]. Group 1: Investment Focus - The focus is on early-commercial-stage life sciences companies, insurers, homebuilders, and select consumer-facing businesses as key sectors for investment [1]. Group 2: Analytical Approach - The author aims to make complex investment theses understandable to a broad audience, ensuring clarity in communication [1].

Financial Performance - KOMZIFTI™ (ziftomenib) generated $2.1 million in net product revenue during the initial five-week commercial availability period ending December 31, 2025[5]. - Kura Oncology received milestone payments of $195 million under a collaboration agreement with Kyowa Kirin in Q4 2025[5]. - The company reported estimated collaboration revenue (non-cash item) for Q4 2025 between $15 million and $17 million[5]. - As of December 31, 2025, Kura had $667.3 million in cash, cash equivalents, and short-term investments[5]. - Kura's financial results for Q4 2025 are subject to completion of financial closing procedures, and actual results may differ materially from preliminary metrics[31]. Product Development and Approval - KOMZIFTI was granted full FDA approval on November 13, 2025, for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation[7]. - KOMZIFTI™ (ziftomenib) is an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia[29]. - The company anticipates non-cash collaboration revenue recognition of $45 million to $55 million in 2026[9]. - Kura plans to accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML and drive quarter-over-quarter growth in net product revenue[9]. - The company aims to present updated data from the KOMET-007 trial in the first half of 2026[9]. - Kura is expanding ziftomenib to non-AML indications and advancing enrollment in various clinical trials throughout 2026[9]. - The company is excited about delivering meaningful impact for patients throughout 2026 and beyond, supported by a deep pipeline of transformative therapies[4]. - Kura Oncology is focused on precision medicines for cancer treatment, with a pipeline targeting hematologic malignancies and solid tumors[29]. - The company is advancing research in menin inhibition and farnesyl transferase inhibition[29]. Risks and Challenges - Forward-looking statements indicate potential risks affecting Kura's future operations and financial results, including market competition and regulatory approval[32]. - Kura anticipates cash runway and collaboration revenue recognition in 2026, but faces risks related to financing and product development[32]. - The company emphasizes the importance of monitoring for unexpected adverse side effects of its product candidates[32]. - Kura's collaboration with Kyowa Kirin is highlighted as a potential risk factor for future success[32]. - The company is committed to developing safe and effective therapeutics, navigating the complexities of drug commercialization[32]. Investor Relations - Investors and media inquiries can be directed to Greg Mann at Kura Oncology[33].

Core Insights - Kura Oncology has launched KOMZIFTI™ (ziftomenib), the first and only once-daily oral menin inhibitor approved for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML) [1][10] - The company reported $2.1 million in net product revenue from KOMZIFTI for the initial five-week period following its commercial sale [1][6] - Kura is positioned for significant advancements in 2026 with a robust pipeline of potentially transformative therapies [1][2] Financial Highlights - KOMZIFTI generated $2.1 million in net product revenue from November 21, 2025, to December 31, 2025 [6] - The company expects milestone payments of $195 million from a collaboration agreement with Kyowa Kirin in Q4 2025 [6] - Estimated collaboration revenue for Q4 2025 is between $15 million to $17 million [6] - Kura had $667.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [6] Recent Program Highlights - KOMZIFTI received full FDA approval on November 13, 2025, for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation [6] - The drug was added to the NCCN Clinical Practice Guidelines as a Category 2A recommended treatment option for adults with R/R NPM1-m AML [6] - Positive data from the ongoing Phase 1a/1b KOMET-007 trial were presented at the ASH 2025 meeting, showing favorable safety and efficacy in combination with venetoclax and azacitidine [6] - The Phase 3 KOMET-017 trial began in September 2025, evaluating ziftomenib in combination with chemotherapy for newly diagnosed patients [6] Expected 2026 Key Milestones - Accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML and drive quarter-over-quarter growth in net product revenue [12] - Present updated data from the KOMET-007 trial and publish combination data in the first half of 2026 [12] - Expand ziftomenib to non-AML indications and advance enrollment in various clinical trials throughout 2026 [12] - Anticipate non-cash collaboration revenue recognition of $45 million to $55 million in 2026 [12]

Core Insights - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, operating in a competitive landscape with peers like Kura Oncology and MacroGenics [1] Financial Performance - Mersana's Return on Invested Capital (ROIC) is -275.91%, significantly lower than its Weighted Average Cost of Capital (WACC) of 7.09%, resulting in a ROIC to WACC ratio of -38.90, indicating poor financial efficiency [2] - Kura Oncology has a ROIC of -45.39% and a WACC of 4.79%, leading to a ROIC to WACC ratio of -9.48, showing better capital management compared to Mersana [3] - MacroGenics has a ROIC of -49.77% and a WACC of 8.83%, achieving a ROIC to WACC ratio of -5.64, indicating it is the most efficient among the peers [3] - Syndax Pharmaceuticals and Deciphera Pharmaceuticals have negative ROICs of -66.59% and -56.11%, respectively, with ROIC to WACC ratios of -11.94 and -10.89, still more favorable than Mersana [4] - Scholar Rock has a ROIC of -101.98% and a WACC of 6.68%, resulting in a ROIC to WACC ratio of -15.26, indicating significant inefficiency but still better than Mersana [4] - Overall, Mersana has the lowest ROIC to WACC ratio among its peers, highlighting its struggle to generate returns over its cost of capital, while MacroGenics stands out with the highest ratio, indicating better performance in capital management [5]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]

Core Insights - Kura Oncology hosted an ASH 2025 analyst and investor event, highlighting significant advancements in menin inhibitors for acute leukemia [1][2] Company Overview - The presentation was led by Troy Wilson, the President and CEO of Kura Oncology, indicating a focus on recent developments and data presented at the conference [1] - The agenda included a review of data presented in an oral session at ASH, emphasizing the importance of the findings for the company and the industry [2]

Kura Oncology ASH 2025 Update Summary Company Overview - **Company**: Kura Oncology (NasdaqGS: KURA) - **Event**: ASH 2025 update call - **Key Product**: Ziftomenib (branded as Comzifti) Industry Context - **Focus**: Acute Myeloid Leukemia (AML) treatment, specifically targeting NPM1 mutant and KMT2A rearranged AML - **Significance**: First ASH conference where ziftomenib is approved, highlighting its potential in AML treatment Core Points and Arguments 1. **Ziftomenib Approval**: Ziftomenib is now approved and available as 200 mg capsules, marking a significant milestone for Kura Oncology and its partners [4][5][6] 2. **Combination Therapy**: The combination of ziftomenib with azacitidine and venetoclax shows promising results in both newly diagnosed and relapsed/refractory AML settings [3][17] 3. **Efficacy Data**: - In newly diagnosed NPM1 mutant AML, the complete response (CR) rate was 73%, with an overall response rate of 89% [11][12] - In relapsed/refractory settings, CR rates were 27% for NPM1 mutant patients and 6% for KMT2A rearranged patients, with overall response rates of 66% and 41% respectively [22][26] 4. **Safety Profile**: The safety profile of ziftomenib in combination with azacitidine and venetoclax was favorable, with low rates of myelosuppression and adverse events such as differentiation syndrome and QTc prolongation [16][20][25] 5. **MRD Negativity**: The minimal residual disease (MRD) negativity rates were 68% at a threshold of 0.1% and 44% at 0.01% in newly diagnosed patients, indicating deepening responses over time [12][61] 6. **Clinical Development Plans**: Kura Oncology is committed to further developing ziftomenib in combination therapies and has a robust clinical development plan, including the ongoing COMET-017 trial [28][29] Additional Important Insights 1. **Patient Demographics**: The median age of patients in the studies was around 75 years, with a significant portion being older and unfit for intensive therapies [8][19] 2. **Long-term Treatment**: The combination therapy allows for prolonged treatment without significant dose reductions, which is crucial for maintaining response and preventing relapse [72][78] 3. **Comparative Efficacy**: The data suggests that ziftomenib may offer enhanced efficacy compared to other menin inhibitors, particularly in terms of MRD negativity and durability of response [40][61] 4. **Future Directions**: Kura Oncology aims to be the first approved menin inhibitor in the newly diagnosed setting, with ongoing trials designed to evaluate the effectiveness of ziftomenib in various patient populations [30][29] Conclusion Kura Oncology's ziftomenib demonstrates significant promise in treating AML, particularly in combination with established therapies. The favorable safety profile and high response rates position it as a potential leader in the evolving landscape of AML treatment. The company is focused on advancing its clinical trials to solidify its role in frontline therapy for AML patients.